ANNALS OF NEUROLOGY, published by Wiley, stands as a leading journal in the field of neurology, renowned for its rigorous peer-reviewed articles that contribute significantly to the understanding of neurological disorders and advances in clinical practices. With an impressive impact factor and ranked Q1 in both neurology and clinical neurology categories, this journal positions itself among the top repositories of cutting-edge research, indexed in Scopus with exemplary ranks in the 98th and 97th percentiles respectively. Since its inception in 1977 and with a commitment to excellence extending to 2024 and beyond, ANNALS OF NEUROLOGY aims to disseminate groundbreaking studies and foster dialogue within the academic community, making it an essential resource for researchers, healthcare professionals, and students dedicated to neurology. Although it does not currently offer open access, its accessibility through institutional subscriptions facilitates widespread scholarly engagement.

Current Neuropharmacology is a premier journal dedicated to advancing the field of neuropharmacology, published by Bentham Science Publishers Ltd in the United Arab Emirates. As a leader in its domain, this journal has achieved a remarkable position in 2023, with Q1 rankings across several categories including Medicine (miscellaneous), Neurology, and Pharmacology. With a robust focus on the latest research related to pharmacological treatments and their neurological implications, Current Neuropharmacology features cutting-edge studies that inform clinical practices and psychiatric care. Although not open access, the journal offers both print and electronic formats to cater to a diverse audience of researchers, healthcare professionals, and students keen on accessing vital information in neuropharmacology. Its high impact within the academia is underscored by impressive Scopus rankings, confirming its importance as a vital resource for the ongoing exploration of mental health and neurotherapeutic innovations. With an engaging scope that encompasses emerging discoveries and clinical advancements, Current Neuropharmacology continues to be an essential platform for scholarly communication in the evolving landscape of neuroscience and pharmacology.

British Journal of Pharmacology is a premier, peer-reviewed journal published by Wiley, specializing in the dynamic field of pharmacology. With a robust impact factor, this journal ranks in the top quartile (Q1) for pharmacology according to the 2023 category rankings, emphasizing its significance and reputation among the global scientific community. As an essential resource for researchers, professionals, and students alike, the journal provides a platform for innovative research spanning foundational studies to clinical applications in pharmacology, toxicology, and pharmaceutics. Since its inception in 1966, the journal has consistently contributed to the advancement of pharmacological science, fostering a deeper understanding of drug action mechanisms and therapeutic advancements. Although primarily subscription-based, the British Journal of Pharmacology is committed to disseminating high-quality research that shapes the future of the field.

CNS & Neurological Disorders-Drug Targets is a distinguished journal that focuses on contemporary research and advancements in the realms of neurology, pharmacology, and drug development. Published by Bentham Science Publishers, this journal serves as an essential platform for researchers, professionals, and students interested in the intricate workings of the central nervous system and the evolving strategies to target neurological disorders through pharmacological innovations. With a robust impact factor reflecting its academic relevance, CNS & Neurological Disorders-Drug Targets is categorized in the Q2 quartile for both Medicine (miscellaneous) and Pharmacology, and Q3 for Neuroscience in the 2023 rankings. The journal's Scopus rankings further reinforce its authority, positioning it within the top half of its categories. Operating out of the United Arab Emirates, the journal has been a loyal contributor to the scientific discourse since its inception in 2006 and will continue until at least 2024, ensuring a dynamic channel for the latest findings and reviews in this vital field. As an open-access publication, it prioritizes accessibility, thus fostering a wider impact among scholars and practitioners alike, making it a valuable resource for all stakeholders in neurological and pharmacological research.

NEUROSCIENCE RESEARCH, published by Elsevier Ireland Ltd, is a leading journal in the field of neuroscience, with a notable reputation for disseminating high-quality research that spans a variety of topics within the discipline. With an ISSN of 0168-0102 and an E-ISSN of 1872-8111, this journal serves as a vital platform for both established researchers and emerging voices in the field. Ranking in the Q2 quartile in both Medicine and Neuroscience categories, it has been recognized as a reliable source of innovative findings since its inception in 1984, with continuous publication through 2024. Although it does not currently offer Open Access options, the journal is indexed in Scopus, holding a significant position at Rank #48/113 in General Neuroscience, reflecting its contribution to advancing the understanding of neural mechanisms across various contexts. With its address anchored in Ireland, NEUROSCIENCE RESEARCH plays an essential role in bridging scientific inquiry and practical applications, making it an indispensable resource for researchers, professionals, and students dedicated to the burgeoning field of neuroscience.

The INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, published by OXFORD UNIV PRESS, is a leading open-access journal in the fields of pharmacology and psychiatry, with an impressive impact factor reflecting its prominence in academic research. Since its inception in 1998, the journal has provided a crucial platform for the publication of high-quality research, offering insights into the effects of neuropharmacological agents on mental health. As of 2023, it ranks in the Q1 category for both Pharmacology and Psychiatry & Mental Health, underscoring its relevance and authority within the scientific community. With notable rankings in various medical subspecialties, it attracts contributions that advance our understanding of psychiatric disorders and therapeutic strategies. The accessible nature of the journal, following its transition to open access in 2015, has expanded its reach, making knowledge and findings readily available to researchers, professionals, and students globally. This commitment to disseminating impactful research ensures the journal remains at the forefront of neuropsychopharmacological advancements.

Science Bulletin is a premier multidisciplinary journal published by Elsevier, renowned for its commitment to advancing scientific knowledge across various fields. With an impressive impact factor and achieving a distinguished Q1 category ranking in 2023 within its multidisciplinary scope, Science Bulletin stands out for its rigorous peer-review process and high-quality research dissemination. Since its inception in 2015, the journal has been pivotal in bridging gaps between diverse scientific disciplines, fostering collaboration and innovation. Researchers and professionals can benefit from its Open Access options, ensuring wider visibility and accessibility of groundbreaking research. With a Scopus rank of #4 out of 171, placing it in the 97th percentile, Science Bulletin continues to set the standard for scholarly excellence, making it an essential resource for those seeking to stay at the forefront of scientific discovery.

Translational Neuroscience, published by DE GRUYTER POLAND SP Z O O, is a leading open-access journal since its inception in 2015, dedicated to the multidisciplinary exploration of neurological research and its clinical applications. With an ISSN of 2081-3856 and an E-ISSN of 2081-6936, the journal serves as a crucial platform for scholars and practitioners to disseminate innovative findings and theoretical advancements in the field of neuroscience. Covering various aspects of general neuroscience, it is ranked in the Q3 quartile for 2023 and positioned at Rank #75 out of 113 in its category, reflecting its growing impact within the scientific community. The journal strives to bridge the gap between laboratory research and clinical practice, fostering collaboration among researchers, clinicians, and educators. The editorial team is committed to maintaining high publication standards that engage the audience with rigorous research while promoting a culture of open science. For those interested in the forefront of neuroscience research, Translational Neuroscience offers an invaluable resource for knowledge and innovation.

NEUROREPORT is a distinguished journal in the field of neuroscience, published by Lippincott Williams & Wilkins. With an ISSN of 0959-4965 and an E-ISSN of 1473-558X, the journal has established itself as a vital platform for disseminating innovative research and developments in the dynamic area of neuroscience since its inception in 1990. Currently, it is positioned in the Q3 category of the 2023 Journal Rankings, reflecting its respectable standing within the community of neuroscience professionals, ranked #74 out of 113 in general neuroscience on Scopus, placing it in the 34th percentile. While it operates on a traditional subscription model, NEUROREPORT is committed to fostering knowledge sharing in the realm of neurobiology, neuropharmacology, and cognitive studies among researchers, professionals, and students alike. With its broad scope and commitment to scientific excellence, the journal continues to be a cornerstone for those seeking to stay ahead in the evolving landscape of neurological research.

The JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, published by the American Society for Pharmacology and Experimental Therapeutics, stands as a pivotal platform in the fields of pharmacology and molecular medicine. With an impressive convergence of knowledge from 1945 to 2024, this esteemed journal is recognized for its rigorous peer-reviewed research, contributing significantly to our understanding of drug action and therapeutic interventions. It holds a commendable position in the Q2 quartile in both Molecular Medicine and Pharmacology, emphasizing its relevance and impact within the contemporary scientific landscape, as evidenced by its Scopus ranking that places it amongst the leading journals in its category. Aimed at researchers, professionals, and students, the journal not only fosters a deeper insight into toxicology, pharmacodynamics, and therapeutic strategies but also encourages innovation through its comprehensive access to groundbreaking experimental methodologies. The journal continues to foster discourse and disseminate research that shapes the future of pharmacological science.